Amantadine, benefit-risk balance in severe brain injury

被引：0
|
作者：
Giacino, J. T.
机构：
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
SYMP03-1
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [41] Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury
    Hughes, S
    Colantonio, A
    Santaguida, PL
    Paton, T
    BRAIN INJURY, 2005, 19 (14) : 1197 - 1206
  • [42] Amantadine for Patients With Severe Traumatic Brain Injury A Critically Appraised Topic
    Spritzer, Scott D.
    Kinney, Carolyn L.
    Condie, John
    Wellik, Kay E.
    Hoffman-Snyder, Charlene R.
    Wingerchuk, Dean M.
    Demaerschalk, Bart M.
    NEUROLOGIST, 2015, 19 (02) : 61 - 64
  • [43] Amantadine as an Aid to Extubation in Severe Acute Brain Injury: A Case Series
    Fang, Benjamin
    Castro, Sergio Angulo
    McHugh, Daryl C.
    NEUROHOSPITALIST, 2024, 14 (03): : 284 - 287
  • [44] Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury
    Giacino, Joseph T.
    Whyte, John
    Bagiella, Emilia
    Kalmar, Kathleen
    Childs, Nancy
    Khademi, Allen
    Eifert, Bernd
    Long, David
    Katz, Douglas I.
    Cho, Sooja
    Yablon, Stuart A.
    Luther, Marianne
    Hammond, Flora M.
    Nordenbo, Annette
    Novak, Paul
    Mercer, Walt
    Maurer-Karattup, Petra
    Sherer, Mark
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09): : 819 - 826
  • [45] Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis
    Mauer, Jonathan
    Bullok, Kristin
    Watt, Stephen
    Whalen, Ed
    Russo, Leo
    Junor, Rod
    Markman, John
    Hauber, Brett
    Tervonen, Tommi
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3837 - 3846
  • [46] Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic
    Cracowski, Jean-Luc
    Molimard, Mathieu
    Richard, Vincent
    Roustit, Matthieu
    Khouri, Charles
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (08) : 959 - 967
  • [47] Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature
    Kurzinger, Marie-Laure
    Douarin, Ludivine
    Uzun, Ievgeniia
    El-Haddad, Chantal
    Hurst, William
    Juhaeri, Juhaeri
    Tcherny-Lessenot, Stephanie
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2020, 11
  • [48] The EMA's CHMP concludes that the benefit-risk balance for MabThera [rituximab] remains positive,
    Reactions Weekly, 2012, 1404 (1) : 3 - 3
  • [49] Statin prescribing according to gender, age and indication: what about the benefit-risk balance?
    Wallach-Kildemoes, Helle
    Stovring, Henrik
    Hansen, Ebba Holme
    Howse, Kenneth
    Petursson, Halfdan
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2016, 22 (02) : 235 - 246
  • [50] Palonosetron Surveillance Data: A Favourable Benefit-Risk Balance in Post-Marketing Use
    Bertazzoli, M.
    Tescione, F.
    Sebastiani, S.
    Cantoreggi, S.
    DRUG SAFETY, 2011, 34 (10) : 922 - 922
12345